Truist Financial Corp Sells 16,398 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Truist Financial Corp lowered its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 1.2% in the 4th quarter, Holdings Channel reports. The fund owned 1,372,424 shares of the company’s stock after selling 16,398 shares during the quarter. Truist Financial Corp’s holdings in Teva Pharmaceutical Industries were worth $30,248,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in TEVA. Smithfield Trust Co raised its position in shares of Teva Pharmaceutical Industries by 55.7% in the 3rd quarter. Smithfield Trust Co now owns 2,739 shares of the company’s stock worth $50,000 after acquiring an additional 980 shares in the last quarter. Wilmington Savings Fund Society FSB bought a new position in shares of Teva Pharmaceutical Industries in the 3rd quarter worth approximately $50,000. Claro Advisors LLC bought a new position in shares of Teva Pharmaceutical Industries in the 3rd quarter worth approximately $52,000. Venturi Wealth Management LLC bought a new position in shares of Teva Pharmaceutical Industries in the 3rd quarter worth approximately $60,000. Finally, Ameliora Wealth Management Ltd. bought a new position in Teva Pharmaceutical Industries during the 4th quarter valued at approximately $66,000. Institutional investors own 54.05% of the company’s stock.

Analyst Ratings Changes

TEVA has been the subject of a number of analyst reports. UBS Group reduced their price objective on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating for the company in a research report on Thursday, January 30th. Barclays reduced their price objective on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a research report on Thursday, January 30th. StockNews.com lowered Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, December 18th. Finally, Piper Sandler raised their price objective on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a research report on Friday, January 17th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $23.57.

Insider Transactions at Teva Pharmaceutical Industries

In other news, Director Roberto Mignone sold 286,000 shares of the firm’s stock in a transaction on Friday, December 20th. The stock was sold at an average price of $22.01, for a total value of $6,294,860.00. Following the transaction, the director now directly owns 695,000 shares in the company, valued at $15,296,950. This trade represents a 29.15 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Company insiders own 0.55% of the company’s stock.

Teva Pharmaceutical Industries Stock Performance

Shares of TEVA opened at $16.55 on Wednesday. The business’s fifty day simple moving average is $19.93 and its two-hundred day simple moving average is $18.50. The company has a current ratio of 0.98, a quick ratio of 0.61 and a debt-to-equity ratio of 2.97. Teva Pharmaceutical Industries Limited has a 12 month low of $12.51 and a 12 month high of $22.80. The company has a market cap of $18.74 billion, a price-to-earnings ratio of -11.41, a P/E/G ratio of 1.39 and a beta of 0.71.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its earnings results on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, beating the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. Research analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.62 earnings per share for the current fiscal year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.